| Year |
Citation |
Score |
| 2013 |
Paulson A, Linklater E, Berghuis B, Melnik M, Woude GV, Graveel CR. Abstract 3022: MET and ERBB2 are coexpressed in ERBB2+ breast cancers and contribute to innate resistance. Cancer Research. 73: 3022-3022. DOI: 10.1158/1538-7445.Am2013-3022 |
0.345 |
|
| 2013 |
Anderson TR, Hubbard G, Daniel AR, Peacock D, Wenger RH, Schörg A, Hoogewijs D, Woude GV, Seagroves TN, Lange CA. Abstract 2927: Breast tumor kinase (Brk/PTK6) mediates hypoxia/HIF-1α-associated breast cancer progression. Cancer Research. 73: 2927-2927. DOI: 10.1158/1538-7445.Am2013-2927 |
0.429 |
|
| 2012 |
Gherardi E, Birchmeier W, Birchmeier C, Woude GV. Targeting MET in cancer: rationale and progress Nature Reviews Cancer. 12: 89-103. PMID 22270953 DOI: 10.1038/Nrc3205 |
0.408 |
|
| 2012 |
Graveel CR, Paulson A, Linklater E, Berghuis B, Feenstra K, Melnik M, Woude GV. Abstract 4864: Targeting MET and ERBB2 signaling in aggressive breast cancers Cancer Research. 72: 4864-4864. DOI: 10.1158/1538-7445.Am2012-4864 |
0.465 |
|
| 2012 |
Gao C, Su Y, Woude GV. Abstract 326: Aneuploidy-driven clonal diversification underlies tumor phenotype switching Cancer Research. 72: 326-326. DOI: 10.1158/1538-7445.Am2012-326 |
0.404 |
|
| 2012 |
Gherardi E, Birchmeier W, Birchmeier C, Woude GV. Erratum: Targeting MET in cancer: rationale and progress Nature Reviews Cancer. 12: 637-637. DOI: 10.1038/Nrc3367 |
0.361 |
|
| 2010 |
Kentsis A, Sanda T, Ngo V, Rodig SJ, Kutok J, Tholouli E, Byers R, Woude GV, Kung AL, Staudt LM, Look AT. Aberrant Expression of Hepatocyte Growth Factor Induces Autocrine MET Activation Providing a Novel Therapeutic Target In Acute Myeloid Leukemia. Blood. 116: 1042-1042. DOI: 10.1182/Blood.V116.21.1042.1042 |
0.363 |
|
| 2010 |
Zhang Y, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, DeKoning T, Eagleson B, Buchanan S, Woude GV. Abstract LB-305: Why two are better than one: Suppression of carcinoma cell growthin vitroand in human HGF/SF transgenic SCID by inhibitors of MET (SGX523) and EGFR (erlotinib) Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-305 |
0.467 |
|
| 2008 |
Knudsen BS, Woude GV. Showering c-MET-dependent cancers with drugs. Current Opinion in Genetics & Development. 18: 87-96. PMID 18406132 DOI: 10.1016/J.Gde.2008.02.001 |
0.422 |
|
| 2004 |
Graveel C, Su Y, Koeman J, Wang LM, Tessarollo L, Fiscella M, Birchmeier C, Swiatek P, Bronson R, Woude GV. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele Proceedings of the National Academy of Sciences of the United States of America. 101: 17198-17203. PMID 15557554 DOI: 10.1073/Pnas.0407651101 |
0.321 |
|
| 2003 |
Riedlinger G, Kridel S, Al-Housseini AM, Brow JM, Bugge TH, Leppla SH, Duesbery N, Woude GV, Frankel A. Metastatic melanoma and matrix metalloproteinases Drugs of the Future. 28: 897-904. DOI: 10.1358/Dof.2003.028.09.857377 |
0.316 |
|
| 2002 |
Hay R, Cao B, Tsarfaty I, Tsarfaty G, Resau J, Woude GV. Grappling with metastatic risk: Bringing molecular imaging of Met expression toward clinical use Journal of Cellular Biochemistry. 87: 184-193. PMID 12552618 DOI: 10.1002/Jcb.10441 |
0.366 |
|
| Show low-probability matches. |